All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

European Commission Approves Belzutifan for VHL Disease–Associated Tumors, Advanced ccRCC

February 18th 2025

The European Commission approved belzutifan for select VHL-associated cancers and advanced clear cell renal cell carcinoma.

Observation Is a Reasonable Alternative to Adjuvant PD-1 Blockade in Stage IIB/IIIC Melanoma

February 18th 2025

Tara C. Mitchell, MD, discusses considerations and lingering questions regarding pre- and post-operative management strategies in stage IIB/IIIC melanoma.

Development of Novel HER2-Targeted Therapies Could Help Reshape Treatment for HER2+ Breast Cancer

February 18th 2025

Kelly E. McCann, MD, PhD, discusses how novel ADCs and targeted therapies could improve treatment strategies in HER2-positive breast cancer.

A Cardiologist Highlights the Interwoven Elements of CVD and Breast Cancer

February 17th 2025

Amy M. Ahnert, MD, details the significance of findings on the link between CVD and breast cancer as well as next steps to further define the connection.

Piflufolastat F18 Imaging Is Associated With High Clinician Confidence in Prostate Cancer Management

February 17th 2025

Piflufolastat F18 imaging impacted treatment decisions and was associated with clinician confidence in prostate cancer management.

FDA Grants Fast Track Designation to IBI363 for Squamous NSCLC

February 17th 2025

The FDA granted fast track designation to IBI363 for squamous non–small cell lung cancer.

OPTYX Study Offers Preliminary Glance Into Real-World Use of Relugolix in Advanced Prostate Cancer

February 17th 2025

Patients with advanced prostate cancer who initiated treatment with relugolix indicated various treatment preferences and reasons for therapy initiation.

Real-World Relugolix Adherence Rates Are High in Patients on Medicare With Prostate Cancer

February 17th 2025

Adherence rates improved the longer patients with metastatic and nonmetastatic prostate cancer received relugolix for a high overall adherence rate.

Denosumab Biosimilars Win FDA, EU Approvals for Select Cancer-Related Bone Loss

February 17th 2025

The FDA and European Commission have approved 2 biosimilars referencing denosumab for cancer-related bone loss and other indications.

Roswell Park-Led Team Proposes CDK2 Enzyme as New Target for Cancer Therapy

February 17th 2025

CDK2 regulates the cell cycle and may have the potential to drive therapeutic resistance to common breast cancer drugs — including CDK4/6 inhibitors.

Investigators Look to Add Duvelisib to Treatment Arsenal of Rare T-Cell Lymphoma Subtype

February 17th 2025

Christopher P. Fox, PhD, discusses the upcoming phase 3 TERZO trial of duvelisib in patients with nodal T-cell lymphoma with follicular helper T phenotype.

Avutometinib/Defactinib Combo Could Fill Sizeable Unmet Need in LGSOC

February 17th 2025

Ritu Salani, MD, MBA, details the significance of trials examining avutometinib plus defactinib and enthusiasm for ADCs in ovarian cancer.

Ide-Cel Boosts Response in Myeloma With < CR After Upfront Auto-HCT and Lenalidomide Maintenance

February 16th 2025

Ide-cel proved feasible and effective in boosting response in patients with myeloma with suboptimal response to standard frontline therapy.

Non-Myeloablative HSCT Regimen Shows Potential for Immune Tolerance in Haploidentical Living Donor Combined Kidney/Hematopoietic Transplant

February 16th 2025

Non-myeloablative HSCT with TLI/TBI/ATG conditioning was safe and active in eliciting immune quiescence and tolerance.

FOXP3/Helios Expression in CD4+ Tcons Correlates With T-Cell Activation After Orca-T in Hematologic Malignancies

February 16th 2025

CD4-, FOXP3-, and Helios-positive conventional T cells were increased in patients receiving Orca-T vs peripheral blood stem cell grafts.

Five Under 5: Top Oncology Videos for the Week of 2/9

February 16th 2025

The top 5 videos of the week cover insights in plexiform neurofibromas, melanoma, myeloma, leukemia, and LBCL.

Tivozanib Elicits Similar PROs With or Without Nivolumab in Advanced Clear Cell RCC

February 15th 2025

No significant differences in PROs were shown between the tivozanib/nivolumab and tivozanib monotherapy arms in patients with advanced clear cell RCC.

Nivolumab Plus Cabozantinib Provides Durable Benefit in First-Line Advanced RCC

February 15th 2025

Nivolumab in combination with cabozantinib displayed a long-term PFS benefit in patients with treatment-naive advanced RCC.

CBM588 Plus Cabozantinib/Nivolumab Shows Early Activity in Metastatic Renal Cell Carcinoma

February 15th 2025

CBM588 plus cabozantinib and nivolumab shows early efficacy in metastatic renal cell carcinoma.

Cabozantinib Plus Nivolumab/Ipilimumab Sustains PFS Benefit in Advanced RCC

February 15th 2025

Efficacy results remained consistent with previous reports in the cabozantinib, nivolumab, and ipilimumab arm for patients with advanced renal cell carcinoma.